RAC1 and inflammatory bowel disease: Azathioprine response is shown in RAC1 WT IBD patients, versus patients carrying RAC11 mutations [118], and patients with active disease which respond to azathioprine therapy show decreased RAC1-GTP and RAC1 expression [119], suggesting that RAC1 could be used as biomarker of azathioprine response.